Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD). Efficacy, safety, and tolerability of esketamine nasal spray in Japanese patients with TR...

Full description

Bibliographic Details
Main Authors: Nagahide Takahashi, Aya Yamada, Ayako Shiraishi, Hiroko Shimizu, Ryosuke Goto, Yushin Tominaga
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Psychiatry
Subjects:
N-methyl-D-aspartate receptor antagonist
Esketamine
Treatment-resistant depression
Nasal spray
Add-on therapy
Efficacy
Online Access:https://doi.org/10.1186/s12888-021-03538-y

Internet

https://doi.org/10.1186/s12888-021-03538-y

Similar Items